Developing the next generation of nanomedicines.
Development of cancer therapies based on the unique functions miRNAs.
Drugs against ‘undruggable’ targets: Small Molecule Helix Mimetics.
Fully synthetic therapeutic vaccines against cancer and persistent viral infections.
A new therapeutic approach in immune-oncology, targeting the tumor microenvironment.
Switching from intravenous-to-oral cancer treatment.
Oncolytic adenovirus technologies.
Enabling endosomal escape of macromolecule therapeutics.
Development of angiogenesis inhibitors for the treatment of solid cancers.
Bispecific antibodies which are targeting solid tumors and blood tumors.
Antibody Drug Conjugate Technologies.
Macrophage Pharma Limited Presents Data on Lead Immuno-Oncology Programme at 32nd Annual Society for Immunotherapy of Cancer (SITC) Conference
Cristal Therapeutics progresses nanomedicine CriPec®-docetaxel to phase 1b development in patients with solid tumours